



RNS: RELEASE

12 June 2025

ImmuPharma PLC
("ImmuPharma" or the "Company")

2025 RESULT OF ANNUAL GENERAL MEETING

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details are contained in the table below.

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2024 together with the reports thereon of the directors and auditors of the Company	88,682,323	74	30,840,722	26	74,472
2. To re-appoint Dr Tim Franklin as a director of the Company	86,938,536	74	31,136,460	26	1,522,521
3. To re-appoint Tim McCarthy as a director of the Company	86,900,286	73	32,579,135	27	118,096
4. To re-appoint Crowe UK LLP as Auditor of the Company	86,901,988	76	27,981,718	24	4,713,811
5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	84,856,858	71	34,558,813	29	181,846
SPECIAL RESOLUTION 6. That, subject to the passing of Resolution 5 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities as set out in the Notice of Meeting	84,812,828	71	34,602,843	29	181,846

As at the date of the AGM, the number of issued ordinary shares of the Company was 499,723,932 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions.

In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total. Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer and Chairman	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 203 650 3650/51
Patrick Claridge, Bob Pountney	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.